Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.37 (
DNA methyltransferase
)
4,983
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Regulator of G-protein signaling 2
(
RGS2
) is a GTPase-activating protein functioning as an inhibitor of G-protein coupled receptors (GPCRs).
RGS2
dysregulation was implicated in solid tumour development and
RGS2
downregulation has been reported in prostate and ovarian cancer progression. However, the molecular mechanism by which
RGS2
expression is suppressed in ovarian cancer remains unknown. The expression and epigenetic regulation of
RGS2
in chemosensitive and chemoresistant ovarian cancer cells were determined by qRT-PCR and chromatin immunoprecipitation assays, respectively. In the present study, the molecular mechanisms contributing to the loss of
RGS2
expression were determined in ovarian cancer. The data indicated that suppression of
RGS2
gene in chemoresistant ovarian cancer cells, in part, due to accumulation of histone deacetylases (HDACs) and
DNA methyltransferase
I (DNMT1) at the promoter region of
RGS2
. Inhibition of HDACs or DNMTs significantly increases
RGS2
expression. These results suggest that epigenetic changes in histone modifications and DNA methylation may contribute to the loss of
RGS2
expression in chemoresistant ovarian cancer cells. The results further suggest that class I HDACs and DNMT1 contribute to the suppression of
RGS2
during acquired chemoresistance and support growing evidence that inhibition of HDACs/DNMTs represents novel therapeutic approaches to overcome ovarian cancer chemoresistance.
...
PMID:Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. 2810 9
